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A Critical Assessment of Feature Selection
Methods for Biomarker Discovery in Clinical
Proteomics*□S
Christin Christin‡§, Huub C. J. Hoefsloot§¶, Age K. Smilde§¶, B. Hoekman‡§,
Frank Suits, Rainer Bischoff‡§, and Peter Horvatovich‡§**
In this paper, we compare the performance of six different
feature selection methods for LC-MS-based proteomics
and metabolomics biomarker discovery—t test, the
Mann–Whitney–Wilcoxon test (mww test), nearest
shrunken centroid (NSC), linear support vector machine–
recursive features elimination (SVM-RFE), principal com-
ponent discriminant analysis (PCDA), and partial least
squares discriminant analysis (PLSDA)—using human
urine and porcine cerebrospinal fluid samples that were
spiked with a range of peptides at different concentration
levels. The ideal feature selection method should select
the complete list of discriminating features that are re-
lated to the spiked peptides without selecting unrelated
features. Whereas many studies have to rely on classifi-
cation error to judge the reliability of the selected bio-
marker candidates, we assessed the accuracy of selec-
tion directly from the list of spiked peptides. The feature
selection methods were applied to data sets with different
sample sizes and extents of sample class separation de-
termined by the concentration level of spiked compounds.
For each feature selection method and data set, the per-
formance for selecting a set of features related to spiked
compounds was assessed using the harmonic mean of
the recall and the precision (f-score) and the geometric
mean of the recall and the true negative rate (g-score). We
conclude that the univariate t test and the mww test with
multiple testing corrections are not applicable to data
sets with small sample sizes (n  6), but their perform-
ance improves markedly with increasing sample size up
to a point (n > 12) at which they outperform the other
methods. PCDA and PLSDA select small feature sets with
high precision but miss many true positive features re-
lated to the spiked peptides. NSC strikes a reasonable
compromise between recall and precision for all data sets
independent of spiking level and number of samples. Lin-
ear SVM-RFE performs poorly for selecting features re-
lated to the spiked compounds, even though the classifi-
cation error is relatively low. Molecular & Cellular
Proteomics 12: 10.1074/mcp.M112.022566, 263–276, 2013.
Biomarkers play an important role in advancing medical
research through the early diagnosis of disease and prognosis
of treatment interventions (1, 2). Biomarkers may be proteins,
peptides, or metabolites, as well as mRNAs or other kinds of
nucleic acids (e.g. microRNAs) whose levels change in rela-
tion to the stage of a given disease and which may be used to
accurately assign the disease stage of a patient. The accurate
selection of biomarker candidates is crucial, because it de-
termines the outcome of further validation studies and the
ultimate success of efforts to develop diagnostic and prog-
nostic assays with high specificity and sensitivity. The suc-
cess of biomarker discovery depends on several factors: con-
sistent and reproducible phenotyping of the individuals from
whom biological samples are obtained; the quality of the
analytical methodology, which in turn determines the quality
of the collected data; the accuracy of the computational
methods used to extract quantitative and molecular identity
information to define the biomarker candidates from raw an-
alytical data; and finally the performance of the applied sta-
tistical methods in the selection of a limited list of compounds
with the potential to discriminate between predefined classes
of samples. De novo biomarker research consists of a bio-
marker discovery part and a biomarker validation part (3).
Biomarker discovery uses analytical techniques that try to
measure as many compounds as possible in a relatively low
number of samples. The goal of subsequent data preprocess-
ing and statistical analysis is to select a limited number of
candidates, which are subsequently subjected to targeted
analyses in large number of samples for validation.
Advanced technology, such as high-performance liquid
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ingly applied in biomarker discovery research. Such analyses
detect tens of thousands of compounds, as well as back-
ground-related signals, in a single biological sample, gener-
ating enormous amounts of multivariate data. Data prepro-
cessing workflows reduce data complexity considerably by
trying to extract only the information related to compounds
resulting in a quantitative feature matrix, in which rows and
columns correspond to samples and extracted features, re-
spectively, or vice versa. Features may also be related to data
preprocessing artifacts, and the ratio of such erroneous fea-
tures to compound-related features depends on the perform-
ance of the data preprocessing workflow (4). Preprocessed
LC-MS data sets contain a large number of features relative to
the sample size. These features are characterized by theirm/z
value and retention time, and in the ideal case they can be
combined and linked to compound identities such as meta-
bolites, peptides, and proteins. In LC-MS-based proteomics
and metabolomics studies, sample analysis is so time con-
suming that it is practically impossible to increase the number
of samples to a level that balances the number of features in
a data set. Therefore, the success of biomarker discovery
depends on powerful feature selection methods that can deal
with a low sample size and a high number of features. Be-
cause of the unfavorable statistical situation and the risk of
overfitting the data, it is ultimately pivotal to validate the
selected biomarker candidates in a larger set of independent
samples, preferably in a double-blinded fashion, using tar-
geted analytical methods (1).
Biomarker selection is often based on classification meth-
ods that are preceded by feature selection methods (filters) or
which have built-in feature selection modules (wrappers and
embedded methods) that can be used to select a list of
compounds/peaks/features that provide the best classifica-
tion performance for predefined sample groups (e.g. healthy
versus diseased) (5). Classification methods are able to clas-
sify an unknown sample into a predefined sample class. Uni-
variate feature selection methods such as filters (t test or
Wilcoxon–Mann–Whitney tests) cannot be used for sample
classification. Other classification methods such as the near-
est shrunken centroid method have intrinsic feature selection
ability, whereas other classification methods such as principal
component discriminant analysis (PCDA) and partial least
squares regression coupled with discriminant analysis
(PLSDA) should be augmented with a feature selection
method. There are classifiers having no feature selection op-
tion that perform the classification using all variables, such as
support vector machines that use non-linear kernels (6). Clas-
sification methods without the ability to select features cannot
be used for biomarker discovery, because these methods aim
to classify samples into predefined classes but cannot identify
the limited number of variables (features or compounds) that
form the basis of the classification (6, 7). Different statistical
methods with feature selection have been developed accord-
ing to the complexity of the analyzed data, and these have
been extensively reviewed (5, 6, 8, 9). Ways of optimizing such
methods to improve sensitivity and specificity are a major
topic in current biomarker discovery research and in the many
“omics-related” research areas (6, 10, 11). Comparisons of
classification methods with respect to their classification and
learning performance have been initiated. Van der Walt et al.
(12) focused on finding the most accurate classifiers for sim-
ulated data sets with sample sizes ranging from 20 to 100.
Rubingh et al. (13) compared the influence of sample size in
an LC-MSmetabolomics data set on the performance of three
different statistical validation tools: cross validation, jack-knif-
ing model parameters, and a permutation test. That study
concluded that for small sample sets, the outcome of these
validation methods is influenced strongly by individual sam-
ples and therefore cannot be trusted, and the validation tool
cannot be used to indicate problems due to sample size or the
representativeness of sampling. This implies that reducing the
dimensionality of the feature space is critical when approach-
ing a classification problem in which the number of features
exceeds the number of samples by a large margin. Dimen-
sionality reduction retains a smaller set of features to bring the
feature space in line with the sample size and thus allow the
application of classification methods that perform with ac-
ceptable accuracy only when the sample size and the feature
size are similar.
In this study we compared different classification methods
focusing on feature selection in two types of spiked LC-MS
data sets that mimic the situation of a biomarker discovery
study. Our results provide guidelines for researchers who will
engage in biomarker discovery or other differential profiling
“omics” studies with respect to sample size and selecting the
most appropriate feature selection method for a given data
set. We evaluated the following approaches: univariate t test
and Mann–Whitney–Wilcoxon test (mww test) with multiple
testing correction (14), nearest shrunken centroid (NSC) (15,
16), support vector machine–recursive features elimination
(SVM-RFE) (17), PLSDA (18), and PCDA (19). PCDA and
PLSDA were combined with the rank-product as a feature
selection criterion (20). These methods were evaluated with
data sets having three characteristics: different biological
background, varying sample size, and varying within- and
between-class variability of the added compounds. Data were
acquired via LC-MS from human urine and porcine cerebro-
spinal fluid (CSF) samples that were spiked with a set of
known peptides (true positives) at different concentration lev-
els. These samples were then combined in two classes con-
taining peptides spiked at low and high concentration levels.
The performance of the classification methods with feature
selection was measured based on their ability to select fea-
tures that were related to the spiked peptides. Because true
positives were known in our data set, we compared perform-
ance based on the f-score (the harmonic mean of precision
and recall) and the g-score (the geometric mean of accuracy).
Statistical Methods for Biomarker Candidate Selection
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Spiked Human Urine Data Set—Fifty urine samples were obtained
from 15 healthy females and 35 healthy males over the age range of
26.9 to 72.9 years. Two hundred microliters were taken from each
sample, creating one pooled urine sample. This pooled urine sample
was used as biological background. The pooled urine was spiked with
a tryptic digest (V5111; Promega, Madison, WI) of bovine carbonic
anhydrase (C3934, Uniprot entry: P00921; Sigma, Steinheim, Ger-
many), as well as with seven synthetic peptides at eight different
dilutions—6.25, 12.5, 25, 50, 100, 200, 400, and 2000 times dilution
(called groups A–H, respectively)—of a stock solution containing
240 M trypsin-digested carbonic anhydrase and the following con-
centrations (in M) of the seven synthetic peptides: VYV, 83; YGGFL,
57; DRVYIHPF, 29; YPFPGPI, 46; YPFPG, 60; GYYPT, 54; and YG-
GWL, 57. At each concentration level, the sample was analyzed five
times using an Agilent G2445A LC/MSD-Trap-SL ion trap mass spec-
trometer (Agilent Technologies, Santa Clara, California, United
States), resulting in 40 LC-MS chromatograms. These chromato-
grams were pre-processed with a constant resolution of 0.1 amu
using the threshold avoiding proteomics pipeline (TAPP) (21) covering
peaks with m/z values of 280 to 1500 amu and retention times
between 30 and 85 min, resulting in a final common peak list of
29,529 features, with 151 of those originating from the added pep-
tides (supplemental Table S1A). Features are items provided by the
data pre-processing pipelines and hold quantitative information about
measured compounds. Features therefore can be related to peptide
isotopologues, peptides, or proteins, but they can be related to
data processing artifacts as well. Positive features are features
selected by the feature selection method, and negative features are
the non-selected ones. Positive and negative features are consid-
ered as true or false according to whether they correspond to
spiked peptides (true) or not (false). Spiked peptides form the basis
of the ground truth. It is therefore crucial to determine accurately all
features in a pre-processed data set that correspond to spiked
peptides. Details of the sample preparation, LC-MS data acquisi-
tion, and method of assignment of features related to spiked pep-
tides are provided in the supplementary material and in Ref. 4. All
subjects that participated in this study gave their oral and/or written
informed consent. The study protocol was in agreement with local
ethical standards and the Helsinki declaration of 1964, as revised in
2004.
Seven data sets were derived from the 40 chromatograms com-
posed of two sample classes with low (class 0) and high (class 1)
spiking levels. These sample classes were obtained by combining
different spiking levels and sample sizes, which resulted in data sets
of different between- and within-class variability of spiked peptides.
Table I provides a description of the most important characteristics of
the derived data sets, and Fig. 5 provides a graphical overview of the
sample size and within- and between-class variability of spiked pep-
tides of the various data sets.
Data set 0a has large between-class variability and a class sample
size of 5. High spiked class 1 was prepared from samples of group A,
and low spiked class (class 0) from samples of group H, leading to low
TABLE I
Description of the sample groups that were combined to give data sets 0a–b, 1a–c and 2a–c. This scheme was used to select files for the 100
repetitions of each combination of feature selection methods and data sets (see supplemental Table S2 for results). One pooled sample was
used to prepare all spiked human urine samples (data sets 0a, 1a–c, and 2a–c) and one porcine CSF sample was used to prepare all spiked
and non-spiked CSF samples (data set 0b)
Data set Between- and within-class variability Sample size per class
Data Set 0a Low within-class variability 0a 5 samples: all samples belongs to groups A (class
1) or class H (class 0)Human urine High between-class variability
High spike class  group A
Low spike class  group H
Data Set 0b Low within-class variability 0b 5 samples: all samples belongs to spiked samples
(class 1) or non-spiked samples (class 0)Porcine CSF High between-class variability
High spike class  spiked samples
Low spike class  non-spiked samples
Data Set 1a–c High within-class variability 1a 6 samples: two samples were randomly taken
from each of the groups A–C (class 1) and F–H
(class 0)
Human urine High between-class variability
High spiked class  combination of groups A–C
Low spike class  combination of groups F–H 1b 12 samples: four samples were randomly taken
from each of the groups A–C (class 1) and F–H
(class 0)
1c 15: all samples from groups A–C (class 1) and
F–H (class 0)
Data Set 2a–c High within-class variability 2a 6 samples: two samples were randomly taken
from each of the groups B–D (class 1) and E–G
(class 0)
Human urine Low between-class variability
High spiked class  combination of groups B–D
Low spike class  combination of groups E–G 2b 12 samples: four samples were randomly taken
from each of the groups B–D (class 1) and E–G
(class 0)
2c 15 samples: all samples from groups B–D (class
1) and E–G (class 0)
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within-class variability corresponding to analytical variability. The six
remaining data sets were combined from three different sample sizes
(6, 12, and 15, denoted by a, b, and c in the data set indexation) and
a high and low between-class variability (indicated as 1 and 2, re-
spectively; see Table I for details). Samples from groups A–C were
used for the high spiked class (class 1), and sample groups F–H were
used for the low spiked class (class 0) for data sets with high be-
tween-class variability (data set 1). Samples from groups B–D were
used for the high spiked class (class 1), and sample groups E–G were
used for the low spiked class (class 0) for data sets with low within-
class variability (data set 2). Samples were selected randomly for data
sets 1a and 2a, with six samples per class, and data sets 1b and 2b,
with 12 samples per class, from the respective spiking groups, and all
samples were used for data sets 1c and 2c, with 15 samples per
class. Feature selection for each combination of feature selection
methods and data sets was repeated 100 times, each time using a
different combination of samples in the inner and outer loop of the
double cross validation procedure.
Spiked Porcine CSF Data Set—The collection, storage, sample
preparation, and LC-MS analysis protocol of the tryptic digest of
porcine CSF was described by Hoekman et al. (4) and Suits et al. (21).
The spiked samples were prepared by mixing 20 l CSF digest with
20 l of a tryptic digest of horse heart cytochrome C (Fluka, part
# 30396) at concentrations of 25 fmol/l. Spiked and non-spiked
samples were aliquoted in five tubes containing 8 l each. Spiked and
non-spiked trypsin-digested CSF was injected five times (4 l from
individual vials) in random order (the amount of injected spiked cyto-
chrome C was 50 fmol) into an Agilent QTOF 6510 equipped with a
chip interface. Raw LC-MS data was exported in mzData format using
Quantitative Analysis (B.03.01) in the MassHunter software package
in centroid mode to limit file size and analysis time. These data were
processed using TAPP (21) in a manner similar to that used for the
human urine dataset. After preprocessing, a total of 9889 features
were detected in this data set, from which 38 corresponded to the
spiked horse heart cytochrome C (see further details on m/z and rt of
spiked-in features in supplemental Table S1B).
Data set 0b was created from non-spiked (class 0) and high spiking
level (class 1) sample classes with a sample size of 5, and with low
within-class variability corresponding to analytical variability and large
between-class variability of spiked-in peptides similar to the human
urine data set 0a.
Biomarker Discovery Methods
Univariate Tests—The parametric univariate t test ranks features
according to their p value and is not a classification method. Because
the data sets contained 6 to 15 samples per class, it was difficult to
test the normality of the data, which in this case is the distribution of
the peak intensities. We therefore also used a non-parametric uni-
variate filter, the mww test. Because the data sets contained a large
number of features, we corrected the calculated p values for multiple
testing using the Benjamini–Hochberg approach (14). A feature was
considered significant when the p value was below 0.05 after multiple
testing corrections.
Semi-multivariate–NSC—The NSC approach aims to find a set of
features that gives the minimum classification error or the highest sum
of correct class probabilities in a set of training samples using double
cross validation by progressively eliminating features that do not
contribute to the construction of the shrunken class centroid. This
method was proposed by Tibshirani et al. for the classification of
cancer samples based on microarray data (15, 16). The double cross
validation scheme for this method is outlined in Fig. 1. Other classi-
fication methods with feature selection used in this study were im-
plemented according to similar double cross validation schemes (see
supplemental Figs. S1 and S2).
The distance dik between a feature i in class k and its respective
overall centroid is calculated as the difference between the within-
class mean x ik and the overall mean x i, normalized to the standard
error. The standard error (Eq. 1) is calculated using the pooled
within-class standard deviation of the respective feature si, a con-
stant s0 (median of the standard deviation si across all features) to
avoid large distances due to small standard deviations, and the
constant xk  1/nk 1/n. The shrinkage threshold  is iteratively
subtracted from this distance, and features whose shrunken distance
in all classes is zero or negative are eliminated. A test sample x* is
attributed to the class to which it has the highest class probability k.
The discriminant score for class k and for test sample x* is kx*,
which is the sum of the standardized squared distances between
each relevant feature in the test sample x* and the kth shrunken
centroid xik corrected by the prior probability k of class k (Eq. 2). This
distance is basically similar to a simple diagonal covariance matrix
between the test sample and the shrunken centroid of the respective
class. Because feature elimination is done univariately but classifica-
tion of the test sample to the class-specific shrunken centroid at a
given shrinkage is calculated multivariately, we call this a semi-mul-
tivariate method.
dik
x ik x i






*  x ik
 2
si
2  2logk (Eq. 2)
Based on the discriminating score, we can calculate the class
probability pˆkx* (Eq. 3), which is the probability of sample x* belong-








Once the class probability has been calculated for each test sam-
ple and for each shrinkage value, the probability of the true class for
each sample is summed up. We now have two measurements, based
on which we select the optimum subset of features: (a) the subset that
minimizes the classification error (Eq. 2), and (b) the subset that
maximizes the sum of true class probabilities (Eq. 3). In our study, the
optimum shrinkage was chosen based on the maximum true class
probability of the test data set, because it gives a continuous plot and
a well-defined optimal shrinkage value. Once the optimum shrinkage
was obtained in the inner cross validation loop (see Fig. 1), it was
applied to the training data set in the inner loop to obtain the optimal
corresponding feature set. Based on this feature set, the discriminant
and the true probability scores were calculated for the independent
test data set in the outer loop to assess the classification model
performance. Because each passage through the outer loop yields a
different value for the optimum shrinkage, we calculated the median
of the correct class probability scores at each shrinkage value from all
the outer loops at the end of the double cross validation scheme.
Fluctuation of the true class probability curves as a function of the
optimal shrinkage values obtained for various outer loop evaluations
reflects the stability of the model and small class differences in the
studied data set. The shrinkage at the maximum of the median true
class probability curve was used to select the optimal feature set
using all samples in the data set.
Multivariate SVM-RFE—A support vector machine (SVM), originally
proposed by Vapnik (22), is a multivariate supervised learning method
Statistical Methods for Biomarker Candidate Selection
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that constructs a hyperplane that separates two groups in a given
data set. Optimal separation between two classes is reflected by
obtaining a hyperplane that has the greatest distance to the nearest
training data point of any class. A sample is viewed as an m-dimen-
sional vector, wherem is the number of features. The goal of the SVM
is to find a hyperplane with dimension m-1 that separates the vectors
based on their respective classes. The hyperplane acts as a discrim-
inant that assigns new data to a given class. SVMs have been widely
used and gained popularity for classification and prediction problems
in medical research in which the feature size far exceeds the available
number of samples, such as in microarray or MS analyses (23–32).
Lately, approaches have been developed to adapt SVM for feature
selection purposes (17, 33, 34). In this study we used a linear SVM
classifier combined with a recursive feature elimination (RFE) approach
for a feature selection method as introduced by Guyon et al. (17). This
approach utilizes the weight vector w, which corresponds to the
weight magnitude of features, as the selection criterion during RFE.
The SVM-RFE procedure works as follows:
1. Initially, using all the features in the training set, train the SVM
classifier.
2. Compute weight vector w.
3. Remove the feature with the lowest weight from the classification
procedure.
4. Train the SVM classifier using the remaining features.
5. Repeat steps 2–4 until there is no remaining feature.
To obtain the optimal feature subset, we used a double cross
validated SVM-RFE. The optimal number of features is determined in
the inner loop. Each time the feature with the lowest weight is elimi-
nated, the classification error based on the new set of features is
calculated. Each inner loop delivers a classification error for a given
set of features, and the rank of each feature is given by its weight. The
optimal number of features is the smallest feature set that gives the
minimum mean classification error. To select the optimum feature
subset, a rank product procedure is applied to the feature rank lists
produced in the inner loops. In the outer loop, the classification error
of the optimal feature subset is computed using an independent test
data set. The exact cross validation scheme is shown in supplemental
Fig. S1.
Multivariate PCDA and PLSDA—PCDA and PLSDA take the rela-
tion between features into account in constructing new feature sets.
Principal component analysis (PCA) constructs new features by find-
ing linear transformations that best explain the variance in the data.
PCA has been combined with linear discriminant analysis as the
classifier applied to the PCA scores. This approach, originally pro-
posed by Hoogerbrugge et al. (19), has been used for feature selec-
FIG. 1. Double cross validation
scheme for the nearest shrunken cen-
troid algorithm. In the inner loops of the
double cross validation scheme, the
sum of the true class probability score at
the respective shrinkage is calculated
(maximum provides the optimal shrink-
age). The final optimal feature set is se-
lected using the shrinkage at the maxi-
mum of the median of the sum of the
true class probability and the shrinkage
plot after the double cross validation
procedure. Performance of the classifi-
cation is measured using optimal param-
eters in the outer loop by calculating the
classification error rate on the outer loop
training data set (double cross validation
error).
Statistical Methods for Biomarker Candidate Selection
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tion and classification in biomedical research using MS (35) or nuclear
magnetic resonance data (36, 37).
PLSDA is a popular method in metabolomic studies (38–44) and
has been shown to be suitable for classification and discrimination in
other applications (18, 45, 46). It consists of a classical PLS regres-
sion analysis in which the response regressor is the class label. PLS
components are built by trying to find a proper compromise between
describing the data set and predicting the response. Further expla-
nation and extensive assessment of this method can be found in the
work of Westerhuis et al. (47–49).
In our study we used a combination of double and single cross
validation procedures for both PCDA and PLSDA. In double cross
validation, the number of principal components (PCs) (for PCDA) and
the number of partial least squares (PLS) components (for PLSDA) are
optimized in the inner loop. At the end of each inner loop, a rank
product procedure (20) is used to rank the features based on their
discriminant coefficients obtained in the inner loop. The outer loop
calculates the classification error from a model that uses the optimal
number of PCs/PLS components obtained in the inner loop and
different numbers of features based on the ranked feature list. The
feature size that gives the minimum classification error in the outer
loops is selected as the optimal number of features. Based on this
double cross validation procedure, the optimal number of PCs/PLS
components and the optimal number of features are selected. To
select the optimum feature sets, we utilized single cross validation
separately from the double cross validation procedure. In the cross
validation loop, the model using the optimal number of components is
built, and the rank product of the discriminant coefficients of the
features is calculated at the end using ranks obtained in each loop.
The optimal feature set is selected from this ranked feature list, the
size of which is given by the preceding double cross validation
procedure. The complete scheme of PCDA and PLSDA in selecting
the optimal feature set is shown in supplemental Fig. S2.
Evaluation Criteria—We performed the evaluation of the described
approaches based on their performance as biomarker selection
methods, rather than as learning algorithms, by measuring each
algorithm’s ability to construct an optimal feature set. In our case,
where the discriminating features in the data sets were known, the
optimal feature sets were supposed to contain only features related to
the spiked peptides (true positives). True positives, false positives,
true negatives, and false negatives were subsequently identified in
each feature set as proposed by a given method constructing a
confusion table (Table II). Several measures were calculated in order
to compare and reveal the characteristics of the algorithms’ perform-
ance (Table III). “Recall” expresses the proportion of selected spiked-
compound-related features relative to all features that are related to
the spiked peptides. “Precision” refers to the proportion of features
that are related to the spiked peptides relative to all features selected
by a given statistical method. The geometric mean accuracy (g-score)
measures the ability of a method to classify both negative (not related
to the spiked peptides) features and positive (spiked-peptide-related)
features correctly. It assesses the overall performance of the feature
selection methods, as it attributes the same importance to both true
positive and true negative features. The f-score is a composite meas-
ure that concentrates on the correct classification of true positive
features based on recall and precision. “Recall” calculates the pro-
portion of the spiked-peptide-related features that were selected as
part of the optimal feature set relative to all spiked-peptide-related
features and assesses the effectiveness of an algorithm in identifying
the true positive features. “Precision” is the proportion of the spiked-
peptide-related features among the selected feature sets and as-
sesses the predictive power of a method. Recall and precision are
balanced in the f-score when the  constant parameter is set to 1 and
is in favor of precision when   1. In our work, we set  equal to 1.
We used the balanced f-score because we were interested in the
correct identification of all spiked-peptide-related features, which
requires taking both recall and precision into account to the same
extent.
In addition to evaluating the optimal feature sets based on the
aforementioned scores, the performance of the methods can be
measured based on several additional criteria: the classification error
of the learning model that is built on its selected features, the com-
plexity/number of the selected features, and the stability of the se-
lected feature subsets. Because the complexity of the learning model
depends on the complexity of the feature set, the selected feature
size has an impact on both performance and interpretability of the
final model.
TABLE II
Confusion table; the columns correspond to features as predicted by a given method, while the rows correspond to the actual class of the
features
Truth/by Methods Selected as optimal features Not selected
Spiked peptide-related features True Positive (tp) False Negative (fn)
Non-spiked peptide-related features False Positive (fp) True Negative (tn)
TABLE III
Definition of the scores that were used to compare the performance of different feature selection methods
Measure Equation




Specificity  True Negative Rate (TNR) tn
tn fp
Geometric Mean Accuracy (g-score) TPR  TNR
f-score 2 1  precision  recall
2  precision recall
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In biomarker discovery research, the size of the feature set deter-
mines the scale of subsequent experiments, such as the identification
of selected peptides or proteins and their validation as biomarkers.
Thus, minimizing the number of false positives (maximizing precision)
is more favorable than maximizing recall. In this study we used
designed data sets in which the true positives were known. Therefore,
recall and precision could be calculated and compared across differ-
ent algorithms. The confidence in selecting a set of biomarker can-
didates can be judged by the stability of the selected feature set upon
repetition of the selection procedure. More confidence is achieved
when the feature selection method gives similar feature sets across
multiple repetitions of cross validation runs using different sample
sets. Though the stability of the obtained feature sets cannot override
the classification error with respect to new test samples, it is still a
useful additional criterion for selecting an optimal feature subset from
different models when the list of spiked-peptide-related features is
unknown.
RESULTS
Six different statistical approaches were evaluated in
LC-MS data sets from human urine and porcine CSF samples
spiked with a range of peptides at different concentration
levels as a simulation of biomarker discovery experiments.
Figs. 2–4 show the bar charts of the medians of the scores
with the respective inter-quartile ranges (IQRs) from 100 rep-
etitions for each combination of a statistical biomarker can-
didate selection method and a data set. The median was used
because it gives robust measurements even when the distri-
bution of the scores is not normal. Fig. 2 shows the natural
logs of the feature size (top) and the number of true positives
(bottom) that are contained in the corresponding feature set.
Fig. 3 shows the recall (top) and precision (bottom) based on
the number of true positive features found in the respective
feature set. Fig. 4 shows the f-scores and g-scores, which are
a composite measure of recall, precision, and true negative
rate. Figs. 3 and 4 include scatter plots of median scores with
error bars of recall (y-axis) and precision (x-axis) and g- (y-
axis) and f-scores (x-axis), respectively. These scores were
used to compare and assess the performance of each method
with respect to sample size, within- and between-class vari-
ability of spiked peptides, type of biological background, and
type of mass spectrometer.
Comparison of Individual Methods—Performance assess-
ment of the various feature selection methods starts with
discussions of results obtained with data sets 0a and 0b.
These two data sets are composed of two different biolog-
ical backgrounds (human urine for 0a and porcine CSF for
0b), a sample size of 5, and a large between-class variability
of spiked peptides. Both classes are composed of samples
of one spiking level, resulting in data sets with low within-
class variability of spiked peptides. In these data sets, iden-
tification of biomarkers represented here as spiked-in com-
pounds is relatively simple. This is followed by a detailed
discussion of the more challenging data sets 1a–1c and
2a–2c, which are composed of human urine samples of
different sample sizes (6, 12, and 15 corresponding to a, b,
FIG. 2. Bar charts of the median (IQR) of the number of selected features (top) and the number of true positives (bottom) for each
combination of feature selection methods and data sets (see Table I for details concerning data sets). Results for the univariate tests
(t test and mww test) on data sets 1a and 2a are denoted by **, and results of the univariate t test on data sets 0a and 0b are denoted by *,
because these methods selected no features at a sample size of 6 or 5 respectively. Univariate t tests on data sets 0a and 0b (5 samples/class)
and univariate tests (t test and mww test) on data sets 1c and 2c (6 samples/class) were performed once including all available samples per
class without repetition.
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and c in our data set notation) and low (8	) and large (32	)
between-class variability of spiked peptides (corresponding
to 1 and 2 in the data set notation). Finding spiked-in com-
pounds in these data sets is more challenging, as the within-
class variability of spiked peptides is much broader (4	) than
the small within-class variability corresponding to analytical
variance in data sets 0a and 0b. The larger within-class vari-
ance of spiked peptides relative to what is expected from
analytical variance in these data sets mimics the expected
behavior of biomarkers better than high and low classes with
fixed spiking levels, because potential biomarkers may be
present in sample groups with a large concentration distribu-
FIG. 3. Bar charts (left) and scatter plot (right) of the median (IQR) of recall (top) and precision (bottom) for each combination of
feature selection methods and data sets. Recall and precision were not available for the t test and the mww test on data sets 1a and 2a,
containing 6 samples (denoted by **), or for the mww test on data sets 0a and 0b, containing 5 samples (denoted by *). Univariate t tests on
data sets 0a and 0b (5 samples/class) and univariate tests (t test andmww test) on data sets 1c and 2c (6 samples/class) were performed once
including all available samples per class without repetition. Gray error bars in the scatter plot show the IQRs of recall and precision.
FIG. 4. Bar charts (left) and scatter plot (right) of the median (IQR) f-score (top) and g-score (bottom) for each combination of
feature selection methods and data sets. The f-score and g-score were not available for the t test and themww test on data sets containing
6 samples (denoted by **) or for the mww test on data sets 0a and 0b containing 5 samples (denoted by *). Univariate t tests on data sets 0a
and 0b (5 samples/class) and univariate tests (t test and mww test) on data sets 1c and 2c (6 samples/class) were performed once including
all available samples per class without repetition. Gray error bars in the scatter plot show the IQRs of recall and precision.
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tion. In addition, compounds may be present in only a fraction
of the samples in sample groups where the within-class con-
centration distribution of spiked compound crosses the limit
of detection. Table I and Fig. 5 contain additional information
on the data set design.
t Test and mww Test—Figs. 3 and 4 show that for data sets
0a and 0b, the t test provides high precision and g-scores
greater than 0.5, resulting in greater precision than with recall.
For these data sets, the t test provides the most complete list
of true positives, with fewer false negatives and false positives
than the other feature selection methods. The biological back-
ground and the type of mass spectrometer have little influ-
ence on the performance of the t test as indicated by the
results of data sets 0a and 0b. For these data sets, the mww
test cannot be applied because of the low sample size; rank-
based mww tests would result in tied ranks and tied p values.
Figs. 2 and 3 show that neither the t test nor the mww test
is capable of finding discriminating features in the two classes
in the more challenging data sets with large within-class vari-
ances of spiked-in compounds when the sample size is low
(data sets 1a and 2a, six samples per class), independent of
the magnitude of the between-class variance of spiked pep-
tides. This improves markedly when the number of samples
per class is increased to 15 (data sets 1c and 2c), at which
point both tests are among the best performing methods. As
expected from univariate methods, the sample size has a
strong influence on performance, with a clear threshold be-
tween no or very poor performance for 6 samples per class
and rather good performance for 15 samples per group. Sim-
ilar results were obtained with data sets 0a and 0b (with a
sample size of 5) and data sets 1b and 1c (with sample sizes
of 12 and 15), indicating that t test performance is influenced
by the within-class variance of the biomarker candidates.
When the within-class variance is low, a lower sample size is
sufficient to reach adequate performance of true positive
selection with a low number of false positives and false neg-
atives. Fig. 3 shows, however, that the high number of true
positives in the results from data sets with 15 samples and a
large between-class variance of spiked compounds (see Fig.
2, data set 1c) are accompanied by a relatively high number of
false positives, lowering precision despite a high recall. De-
spite modest precision, univariate feature selection methods
gave the highest g-scores and f-scores for these data sets
(Fig. 4, data sets 0a, 0b, and 1c), showing that the trade-off
between recall and precision results overall in the best per-
formance with respect to g- and f-scores. It is interesting to
note that univariate tests gave a lower recall but a higher
precision when between-class variance decreased (Fig. 3,
data set 2c), which is primarily attributable to a 2-fold lower
number of detected true positives (Fig. 2, data set 2c). The
same tendency was observed for data sets 1b and 2b, with 12
samples per class. The composite f-score and g-score show
that the overall performance of univariate feature selection
methods is mainly affected by the sample size and within-
class variability, and slightly by the between-class variability,
of spiked-in peptides. It shows as well that standard univari-
ate feature selection methods perform as well as or even
better than the more sophisticated multivariate or semi-mul-
tivariate methods with a class size of 15 samples in the case
of large within-class variability of spiked-in peptides, or with a
FIG. 5. Overview of the two best performing feature selection statistical methods for data sets of different sample sizes and
between- and within-class variability of spiked peptides based on the f-score. NSC shows the best performance for data sets with 6
samples independent of between- and within-class variability of spiked peptides, whereas univariate tests rank on top when the sample size
increases to 15 samples per class or for low-sample-size data sets (0a and 0b) with low within-class variability of spiked peptides.
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smaller sample size of 5 when the within-class variability of
spiked-in peptides is negligible.
NSC—The use of NSC resulted in the highest number of
true positive features with a relatively low number of false
positive features in data sets with low within-class variability
(data sets 0a and 0b) regardless of the biological background
(urine or CSF) or the type of mass spectrometer (low or high
resolution), leading to high precision. However, NSC did not
provide a complete list of true positive features, resulting in
low recall (0.185 in the case of human urine in data set 0a, and
0.50 for CSF in data set 0b). Similarly, this algorithm provided
the highest number of true positives for the smallest sample
size of 6 samples per class with large within-class variance of
spiked-in peptides (data sets 1a and 2a), but at the expense
of selecting a fairly high number of features that were not
related to the spiked peptides (Fig. 2, data sets 1a and 2a).
This leads to high recall but intermediate precision relative to
the other algorithms (Fig. 3, data sets 1a and 2a). Notably,
PLSDA outperformed NSC with respect to precision for data
sets with a low number of samples because of the very low
number of selected features in data sets with large within-
class variability of spiked-in compounds (data sets 1a and 2a)
that are not related to the spiked peptides (false positives).
NSC remains among the better performing algorithms for data
sets with a higher number of samples (data sets 1b, 1c, 2b,
and 2c), showing fairly stable performance across all evalu-
ated data sets, which is also reflected in rather similar g-
scores and f-scores (Fig. 4). NSC benefits from increasing
sample size when it comes to precision (Fig. 3), as it selects
fewer features that are not related to the spiked peptides,
whereas the number of true positives decreases only slightly,
resulting in improved precision without a significant sacrifice
of recall. It is also noteworthy that the robustness of the
statistical model improved with increasing sample size based
on the reduced IQR (see error bars in Figs. 2–4). The differ-
ence in recall and precision between data sets with 12 and 15
samples was not significant (Fig. 3, data set 1b versus 1c, and
2b versus 2c). Higher recall and slightly lower precision were
observed for data sets with large class separation (1b and 1c)
relative to those with small class separation (Fig. 3, data sets
1b and 1c versus data sets 2b and 2c), which holds also for
both the f-score and the g-score (Fig. 4).
SVM-RFE—SVM-RFE selected the highest number of fea-
tures in almost all data sets, whereas the number of selected
true positives was lower than for most of the other methods,
resulting in many false positives (Fig. 2). There were large
differences between the number of selected features in data
sets with low within-class variability of spiked-in peptides
(4100 and 10 selected features in data sets 0a and 0b, re-
spectively). This large difference may be explained by the
poor performance of SVM-RFE, as no true positive was in-
cluded in the low number of selected features in the porcine
CSF data set 0b, and only 38 true positives were included in
the selected 4100 features from the human urine sample. The
results of both data sets seem therefore to be a random
selection of features without any preference to selectively
enrich true positives. Even though there is a trend toward
better performance as the sample size and between-class
variability of spiked peptides increase (data set 1), scores
remain low, with a maximum recall of 0.2 and a maximum
precision of 0.05 (Fig. 3). The large number of selected fea-
tures lowers precision and, consequently, the f-score (Figs. 3
and 4). The g-score is also lower than for most other algo-
rithms. It is a property of SVM that many correlated variables
receive almost equal weights, which means that the weight of
a feature is not a very useful measure for feature selection.
This could be why the size of the feature set selected by
SVM-RFE is rather large. Our results with peptide-spiked
human urine or porcine CSF samples show that the SVM-RFE
approach is not suitable for the selection of biomarker
candidates.
PCDA—For most of the studied data sets, PCDA tended to
select a low number of true positive features and a low num-
ber of features resulting in low recall and high precision,
notably for large sample sizes, although results fluctuated
considerably (Figs. 2 and 3, data sets 1b, 1c, 2b, and 2c).
PCDA may thus be considered a fairly “conservative” ap-
proach to biomarker discovery, as the selected feature list has
a relatively high content of true positive features. In contrast to
NSC and the univariate tests (t test and mww test), PCDA
tends to select fewer features from data sets with high be-
tween-class variability (data set 1); this is most pronounced
for data set 1c. While the number of selected features is low
(mean of 5.3 
 0.8), the selection contains essentially only
true positive features (mean of 5.13 
 0.8), resulting in very
high precision (mean of 0.97 
 0.06) in data sets 1a–1c and
2a–2c. This may be considered a desirable characteristic of
this approach when it comes to subsequent validation of the
selected biomarker candidates in large numbers of samples.
However, most of the true positives are missed using this
statistical approach. Accurate selection of a low number of
true positive features with low recall is reflected by the poor
values of the composite measure f-scores and g-scores (Fig.
4). The precision of the PCDA method is lower in data sets
with low sample sizes irrespective of the between- and within-
class variability of spiked-in peptides (Fig. 3, data sets 0a, 0b,
1a, and 2a), which makes the method adequate for biomarker
candidate selection in data sets having a sample size equal to
or greater than 12 samples per group. Similar results for data
sets 0a, 0b, 1a, and 2a show that the performance of PCDA is
not affected by the biological background, resolution of the
mass spectrometer, or within-class variability of spiked
peptides.
PLSDA—The most striking characteristic of PLSDA is the
extremely high precision regardless of the sample size or the
class separation (Fig. 3) in almost all data sets of spiked
human urine samples. Surprisingly, the analysis of spiked
trypsin-digested porcine CSF yielded lower precision due to a
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relatively low number of true positives among the selected
features (1 out of 6), which could be related to the lower
number of spiked features (38, compared with 151 in human
urine samples). The selection of a low number of true positive
features with high precision is advantageous in cases when
subsequent biomarker validation is tedious, requires signifi-
cant effort, and resembles the results obtained with PCDA.
The stability of the model underlying feature selection in-
creases with increasing sample size, as shown by the reduced
IQR. High precision comes at a price, however, as the number
of selected true positives is small relative to the number of
expected true positive features based on the spiked peptides
(Fig. 2). The low number of selected true positives likely re-
sults from the facts that PLSDA and PCDA select with high
probability the most abundant features with relative low error
and that the cut-off value for the rank products for selecting
features is too conservative. Because signals related to the
spiked peptides are highly correlated, PCDA and PLSDA se-
lect only a few of them that represent the between-class
variability of spiked peptides well. Globally, PLSDA is not
really affected by the strength of the between-class varia-
bility of spiked peptides in the data set, because the pat-
terns of recall and precision in data sets 1 and 2 are com-
parable (Fig. 3). When sample size increases, recall
improves slightly, although it remains low overall. In con-
trast to PCDA, PLSDA also shows high precision on data
sets with a low sample size (Fig. 3, data sets 0a, 1a, and 2a),
making this method more adequate for accurately selecting
true positive features in data sets with only 6 samples per
group than PCDA.
Comparison between Methods—Although all methods ben-
efit from a larger sample size, only some of them are affected
by the between- and within-class variability of spiked pep-
tides. The univariate t test and mww test results are strongly
affected by the between- and within-class variability of spiked
peptides (based on the comparison of f-score, g-score, recall,
and precision). Furthermore, they require a minimum sample
size to function. Multivariate methods that use feature trans-
formation prior to selecting a given feature set, such as
PCDA and PLSDA, are not strongly affected by the be-
tween-class variability of spiked peptides or sample size.
The performance of NSC is overall rather independent of the
between-class variability of spiked peptides and sample
size.
When the characteristics of the data set were profitable
(large sample size and high between-class variability of
spiked peptides), univariate methods (t test and mww test)
performed best, because they assigned most of the true
positives within a reasonably sized total feature set. They
were furthermore the fastest and simplest methods to use.
Univariate methods failed when the sample size was small
(e.g. six samples per class), except when the between-class
variability of spiked peptides was high and the within-class
variability of spiked peptides was low. This latter condition is,
however, very unlikely in biomarker discovery, in which com-
pounds have large within-class variability due to large biolog-
ical variability and tend to be present to some extent in all
sample classes. Based on the f-score, g-score, recall, and
precision, the semi-multivariate NSC outperformed all other
methods, including multivariate methods, in terms of feature
selection, as it strikes the best balance between recall and
precision, keeping both f-scores and g-scores high. The mul-
tivariate methods PLSDA and PCDA provided high-quality
feature sets that are reflected in high precision approaching
100% at the expense of a low recall. Globally speaking, NSC
is applicable to all tested data sets and might be considered
a good compromise when performing small-scale biomarker
discovery studies.
Additional assessment criteria are the classification error
rate or sum of true class probability in the case of NSC and
the stability of the models. When repeating the calculation a
number of times, the result is more trustworthy if all repeti-
tions yield similar conclusions. To test this, we assessed the
variability of feature selection performance across 100 repe-
titions in data sets with sample sizes of 12 and 15 (1b, 1c, 2b,
and 2c) based on g-score and f-score, variation of the clas-
sification error rate, and the sum of true class probability in the
case of NSC. The variability of g-scores and f-scores was
measured using the IQR for a given data set. In general, there
was a tendency for the IQR to decrease with all approaches
as the number of samples increased (see error bars in Figs.
2–4), except for SVM-RFE, which might be due to the poor
overall performance of the approach resulting in quasi-ran-
domly selected feature sets.
The variability of the classification error rate or the sum of
true class probability in each cross validation loop reflects the
stability of the model that is used as a classifier. Two different
kinds of classification error can be derived from such a double
cross validation scheme: the error in the inner loops, which
determines the optimal values for the parameters, and the
classification error in the outer loops when using optimal
parameter values, which assesses the error rate of the optimal
model for classifying new sets of samples. The inner loop
classification error rate or sum of true class probability shows
considerable dependence on the sample size of the data sets,
as shown in supplemental Figs. S3–S6. However, the be-
tween-class variability of spiked peptides does not have an
effect on inner loop classification error rates or on the sum of
true class probabilities. The error in the outer loop averaged
20% for data sets with high between-class variability of
spiked peptides (1a–1c) and 30% for data sets with low
between-class variability of spiked peptides (2a–2c) inde-
pendent of the applied method. The fluctuation of the inner
loop classification error rate or the sum of true class proba-
bility is due to different values for the optimal parameters
determined in the inner loops obtained from varying training
samples sets and can be assessed in a classification error or
sum of true class probability against a parameter plot. These
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plots indicate whether the minimum error, which determines
the optimum parameter value, is located in a smooth/stable
region. All plots that were used to determine the optimal
parameters in this study are shown in supplemental Figs.
S3–S6. The spread of the error decreased with increasing
sample size, showing that the stability of the models in-
creased with increasing sample number. The results show
also that it is not justifiable to rely on a classification result
from a model obtained from a training data set with only six
samples per group, except in the case of the NSC algorithm.
To assess the variability of the selected feature sets deliv-
ered by each method, we compared the count of features that
were selected at least once across 100 repetitions (unique
features) relative to the count of features that were selected in
each repetition (common features) (shown in supplemental
Table S2). The stability of the feature set is not available
because only one repetition was possible for all feature se-
lection methods for data sets 0a and 0b because of the low
sample size. Similarly, the stability of the feature set was not
determined for the mww test or the t test for data sets 1c and
2c because of the lack of a double cross validation scheme for
these methods. From this result, NSC produced the most
stable feature set of all methods, as shown by the high ratio of
the number of common features to the number of unique
features.
DISCUSSION
We have assessed different feature selection methods with
respect to their capacity to deliver biomarker candidates from
a number of well-controlled data sets that were obtained via
LC-MS analysis of peptide-spiked human urine or trypsin-
digested porcine CSF samples. Six widely used feature se-
lection methods were compared and their performance meas-
ured based on how well they found true positives (features
that are related to the spiked peptides) and how well they
avoided false positives (all other features) for data sets with
different sample sizes and between- and within-class varia-
bility of spiked peptides. We derive six main conclusions from
this study. (1) As expected, all methods benefit from a larger
sample size. (2) Univariate methods and semi-multivariate
methods are more sensitive to the between- and within-class
variability of spiked peptides, whereas multivariate methods
(especially PLSDA) are hardly affected by the between-class
variability of spiked peptides. (3) SVM-RFE performed poorly
on all data sets with respect to selecting relevant features,
showing that the weight vector is not a suitable criterion for
feature selection/elimination. (4) True multivariate methods
like PCDA and PLSDA aim at high precision by sacrificing
recall (i.e. they are conservative with respect to selecting true
positive features). PLSDA performs better than PCDA for data
sets with a low sample size when the within-class variability of
spiked peptides is high. (5) The semi-multivariate NSC strikes
the best compromise between recall and precision regardless
of sample size and between- and within-class variability of
spiked peptides. (6) The performance of feature selection
methods shows little dependence on the number of discrim-
inating features, the biological background, or the type of
mass spectrometer used for data acquisition. Fig. 5 provides
an overview of the best performing feature selection methods
based on the f-score for data sets with different within- and
between-class variability of spiked peptides and sample size.
The figure provides a summary concerning the choice of a given
feature selection method and should help practitioners select
the most suitable method for biomarker discovery studies.
Because biomarker discovery is usually intended to support
clinical diagnosis, it is advantageous to obtain a discriminat-
ing feature set with a minimum number of false positives and
with the potential to classify new sets of samples correctly.
Based on this criterion, PLSDA is a good choice because of
its excellent precision. When additional, correlated discrimi-
nating features are required—for example, to support path-
way analysis—PLSDA might miss relevant features that could
be informative. In that case, NSC provides a better compro-
mise between recall and precision, with a higher number of
true positives at a reasonable false positive rate. In cases in
which data from more samples are available (more than 15
samples per group/class in our case), univariate tests (t test or
mww test with multiple testing correction) are able to identify
biomarker candidates with high confidence. For classes with
low sample numbers (six samples per class in our case), NSC
has the greatest potential to select biomarker candidates
successfully. However, our results show that there is consid-
erable danger in relying on results from data sets with such a
small sample size, as classification models and the values for
optimized parameters are prone to significant fluctuations,
making biomarker selection uncertain.
To enhance the application of the presented feature selec-
tion methods and further the use of our test data sets to
assess other feature selection algorithms, we have made the
source code and preprocessed LC-MS data with descriptions
of spiking levels and spiked compounds and indices of
spiked-in-peptide-related features available through the
source code repository of Netherlands Bioinformatics Centre
(link is on page 2 in supplementary material).
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